Journal of the American Academy of Dermatology · 2025
Real-world effectiveness and safety of oral Janus kinase inhibitor in vitiligo: A retrospective study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shi Xiaoyi, Yuan Yukun, Sun Rongsi, Zhu Mengyi, Du Juan, Wang Fang, Ding Xiaolan
Аннотация
BACKGROUND: Increasing numbers of studies have demonstrated that oral Janus kinase inhibitors (JAKis) are effective in the treatment of vitiligo. However, large-scale data on their effectiveness and safety remain limited.
OBJECTIVE: We aimed to assess the effectiveness and safety of oral JAKi in vitiligo treatment and explore potential predictive factors associated with response to JAKi under real-world conditions.
METHODS: A retrospective study was conducted in vitiligo patients who had received oral JAKi for at least 3 months. The overall response rate was the total percentage of patients who achieved >25% repigmentation. Multivariable logistic regression analysis identified predictors for response and oral JAKi.
RESULTS: A total of 96 patients were included, 86 (89.6%) of whom achieved different degrees of repigmentation. The overall response rate was 55.2%, and the rate of marked repigmentation (≥76%) was 9.4%. Age, history of phototherapy, and oral JAKi administration for more than 6 months were independent predictors of response to JAKi. No severe adverse events were observed.
LIMITATIONS: A single-center study with limited patients.
CONCLUSION: Oral JAKi were effective and safe for patients with vitiligo. Patients taking oral JAKi for more than 6 months had better outcomes than those who received JAKi for a shorter period.
OBJECTIVE: We aimed to assess the effectiveness and safety of oral JAKi in vitiligo treatment and explore potential predictive factors associated with response to JAKi under real-world conditions.
METHODS: A retrospective study was conducted in vitiligo patients who had received oral JAKi for at least 3 months. The overall response rate was the total percentage of patients who achieved >25% repigmentation. Multivariable logistic regression analysis identified predictors for response and oral JAKi.
RESULTS: A total of 96 patients were included, 86 (89.6%) of whom achieved different degrees of repigmentation. The overall response rate was 55.2%, and the rate of marked repigmentation (≥76%) was 9.4%. Age, history of phototherapy, and oral JAKi administration for more than 6 months were independent predictors of response to JAKi. No severe adverse events were observed.
LIMITATIONS: A single-center study with limited patients.
CONCLUSION: Oral JAKi were effective and safe for patients with vitiligo. Patients taking oral JAKi for more than 6 months had better outcomes than those who received JAKi for a shorter period.